


**SANDU PHARMACEUTICALS LIMITED**  
 REGD. OFFICE- PLOT NOS. 25, 26, 29 & 30, PILERNE INDUSTRIAL ESTATE,  
 KARRA, SALIGAO, BARDEZ GOA- 403 611.

**STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER ENDED 30/05/2015**

PART I		(In Lacs)				
Particulars	3 months ended	3 months ended	Corresponding	Year to date	Previous year	
	30/05/2015	31/03/2015	3 months ended	figures for	ended	
			30/05/2014	current period	31/03/2015	
			the previous	ended		
			year	20/05/2015		
(Refer Notes Below)	(Unaudited)	(Audited)*	(Unaudited)	(Unaudited)	(Audited)	
1 Income from continuing operations						
(a) Net sales/income from operations (Net of excise duty)	891.57	1,251.06	914.50	891.57	4,440.20	
Loss: Trade Discount	107.96	140.70	67.45	107.96	480.24	
	<b>883.59</b>	<b>1,140.77</b>	<b>827.05</b>	<b>883.59</b>	<b>3,960.16</b>	
(b) Other operating income	-	-	-	-	-	
Total income from operations (net)	<b>883.59</b>	<b>1,140.77</b>	<b>827.05</b>	<b>883.59</b>	<b>3,960.16</b>	
2 Expenses						
(a) Cost of materials consumed	121.78	275.82	180.34	121.78	675.18	
(b) Purchases of traded goods	514.36	520.89	244.45	514.36	1,302.20	
(c) Changes in inventories of finished goods, work-in-progress, traded goods & Stock in Transit	(187.77)	95.73	29.59	(187.77)	143.87	
(d) Employee benefits expense	104.64	87.17	85.45	104.64	355.29	
(e) Depreciation and amortisation expense	13.32	10.69	15.32	13.32	52.49	
(f) Other expenses	209.84	369.29	250.86	209.84	1,145.09	
Total expenses	<b>636.20</b>	<b>1,109.49</b>	<b>705.54</b>	<b>636.20</b>	<b>3,773.95</b>	
3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	47.38	31.18	41.81	47.38	185.20	
4 Other income	3.48	5.78	1.47	3.48	13.80	
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	<b>50.84</b>	<b>36.96</b>	<b>44.08</b>	<b>50.84</b>	<b>199.00</b>	
6 Finance costs	34.08	33.89	35.66	34.08	132.01	
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	<b>16.76</b>	<b>3.07</b>	<b>10.43</b>	<b>16.76</b>	<b>62.87</b>	
8 Exceptional items	0.00	0.00	0.00	0.00	0.00	
9 Profit / (Loss) from ordinary activities before tax (7+8)	<b>16.76</b>	<b>3.07</b>	<b>10.43</b>	<b>16.76</b>	<b>62.87</b>	
10 Tax expense	3.62	7.99	30.80	3.62	21.61	
11 Net Profit / (Loss) from ordinary activities after tax (9+10)	<b>13.14</b>	<b>(4.92)</b>	<b>11.01</b>	<b>13.14</b>	<b>41.26</b>	
12 Extraordinary items (net of tax expense)	0.00	0.00	0.00	0.00	0.00	
13 Net Profit / (Loss) for the period (11+12)	<b>13.14</b>	<b>(4.92)</b>	<b>11.01</b>	<b>13.14</b>	<b>41.26</b>	
14 Share of profit / (loss) of associate*	0.00	0.00	0.00	0.00	0.00	
15 Minority interest *	-	-	0.00	-	-	
16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associate (13+14+15)	<b>13.14</b>	<b>(4.92)</b>	<b>11.01</b>	<b>13.14</b>	<b>41.26</b>	
17 Paid-up equity share capital (Face Value of the Shares that are received)	708.10	708.10	708.10	708.10	708.10	
18 Reserve including Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	
19 (a) Foreign per share (before extraordinary items)	0.19	(0.07)	0.15	0.19	0.59	
(b) of 10 (c) each (not annualised)	-	-	-	-	-	
(d) Basic	-	-	-	-	-	
(e) Diluted	-	-	-	-	-	
19.1 Earnings per share (after extraordinary items)	-	-	-	-	-	
(a) of 10 (c) each (not annualised)	-	-	-	-	-	
(b) Basic	-	-	-	-	-	
(c) Diluted	-	-	-	-	-	

PART - I					
PARTICULARS OF SHAREHOLDING					
<b>A</b>					
1	Public shareholding				
	- Number of shares	5,895,310.00	5,895,540.00	5,825,330.00	5,895,530.00
	- Percentage of shareholding	55.01	55.01	55.01	55.01
2	Promoters and Promoter Group Shareholding				
a)	Pledged / Encumbered				
	- Number of shares				
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)				
	- Percentage of shares (as a % of the total share capital of the company)				
b)	Not - encumbered				
	- Number of shares	3,185,690.00	3,185,690.00	3,185,690.00	3,185,690.00
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	44.99	44.99	44.99	44.99
<b>B</b>					
DIVIDEND COMPLAINTS					
3 months ended (30/06/2016)					
	Pending at the beginning of the quarter			Nil	
	Received during the quarter			Nil	
	Disposed of during the quarter			Nil	
	Remaining unresolved at the end of the quarter			Nil	
<b>Notes to Accounts</b>					
1. The Auditors have conducted Limited Review of the financial results for the quarter ended June 30, 2016. The Unaudited Financial results have been recommended by the audit committee at its meeting held on August 13, 2016 and Approved by the Board of Directors at its meeting held on August 13, 2016					
<p>For SANDU PHARMACEUTICALS LIMITED</p>  <p>UMESH S. KARADU MANAGING DIRECTOR DIR-01132142 PLACE: MUMBAI DATE: 30th August, 2016</p>					

### **Limited Review Report**

We have reviewed the accompanying statement of unaudited financial results of **SANDU PHARMACEUTICALS LIMITED** for the period ended 30/06/2015. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2400, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the accounting standards referred to in Section 211 (3C) of the Companies Act, 1956 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with stock exchanges including the manner in which it is to be disclosed, or that it contains any material misstatement.



For Joshi Joshi & Co.  
Chartered Accountants  
(FRN: 104393w)

A handwritten signature in black ink, appearing to read "M. M. Joshi".

(M. M. Joshi)  
Proprietor  
M.No-42466 of 89

Mumbai

Date: 13/08/2015